Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Neoplasms × belzutifan × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Renal Cell 17 Kidney Neoplasms 8 Parkinson Disease 4, Autosomal Dominant Lewy Body 5 von Hippel-Lindau Disease 4 Neoplasm Metastasis 2 Recurrence 1 Pheochromocytoma 1 Paraganglioma 1 Neoplasms 1 Metastatic Castration-Resistant Prostate Cancer 1 Glioblastoma 1 Carcinoma 1 Breast Neoplasms 1 Adenoma, Islet Cell 1

Interventions

pembrolizumab 115 Paclitaxel 92 Gemcitabine 89 Carboplatin 76 Nivolumab 57 Bevacizumab 57 Docetaxel 56 Cisplatin 48 Pemetrexed 45 Fluorouracil 42 Cyclophosphamide 39 Cetuximab 34 Capecitabine 33 Leucovorin 32 Irinotecan 32 venetoclax 31 Sorafenib 31 trametinib 29 atezolizumab 28 Erlotinib Hydrochloride 28 Dexamethasone 27 130-nm albumin-bound paclitaxel 26 Drug Therapy 25 Ipilimumab 24 Epoetin Alfa 24 Doxorubicin 23 Oxaliplatin 21 Rituximab 20 Prednisone 20 Lapatinib 20

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04976634 2025-04-06

MK-6482-016

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡